Commentary on DeMets et al: The need for greater transparency regarding data monitoring committee charters

Abstract

Get full access to this article

View all access options for this article.

References

DeMets

Zarin

Rockhold

, et al. Bringing data monitoring committee charters into the sunlight. Clin Trials (in press).

DeMets

Fleming

. Achieving effective informed oversight by DMCs in COVID clinical trials. J Clin Epidemiol 2020; 126: 167–171.

Krumolz

Ross

Presler

, et al. What have we learnt from Vioxx? BMJ 2007; 334(7585): 120–123.

Food and Drug Administration. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees, https://www.fda.gov/media/75398/download (accessed 22 March 2023).

Kahneman

. Thinking, fast and slow. New York: Macmillan, 2011.

Grady

. Institutional review boards: purpose and challenges. Chest 2015; 148(5): 1148–1155.

Eckstein

Rid

Kamuya

, et al. The essential role of Data and Safety Monitoring Boards (DSMBs) in ensuring the ethics of global vaccine trials to address coronavirus disease 2019 (COVID-19). Clin Infect Dis 2021; 73(11): 2126–2130.

Taylor

Chaisson

Sugarman

. Enhancing communication among data monitoring committees and institutional review boards. Clin Trials 2008; 5(3): 277–282.

Office of Science and Technology Policy. Fact sheet: Biden-Harris Administration announces new actions to advance open and equitable research, https://www.whitehouse.gov/ostp/news-updates/2023/01/11/fact-sheet-biden-harris-administration-announces-new-actions-to-advance-open-and-equitable-research/?